These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 15662231

  • 1. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
    Wood JM, Schnell CR, Cumin F, Menard J, Webb RL.
    J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
    [Abstract] [Full Text] [Related]

  • 2. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
    van Esch JH, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH.
    J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [Abstract] [Full Text] [Related]

  • 4. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M, Ménard J, Bissery A, Guyene TT, Bura-Rivière A.
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [Abstract] [Full Text] [Related]

  • 5. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N, Varagic J, Ahmad S, VonCannon JL, Simington SW, Wang H, Groban L, Brosnihan KB, Nagata S, Kato J, Kitamura K, Gomez RA, Lopez ML, Ferrario CM.
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, Camisasca RP.
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [Abstract] [Full Text] [Related]

  • 7. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
    Moniwa N, Varagic J, Ahmad S, VonCannon JL, Ferrario CM.
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
    [Abstract] [Full Text] [Related]

  • 8. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats.
    Webb RL, Navarrete AE, Davis S, de Gasparo M.
    J Hypertens; 1998 Jun; 16(6):843-52. PubMed ID: 9663925
    [Abstract] [Full Text] [Related]

  • 9. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
    Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Müller DN.
    Hypertension; 2005 Sep; 46(3):569-76. PubMed ID: 16103264
    [Abstract] [Full Text] [Related]

  • 10. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A.
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J, Wuerzner G, Jensen C, Brunner HR.
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [Abstract] [Full Text] [Related]

  • 12. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S, Valencia J, Kemp C, Zhao C, Yeh CM, Bizot MN, Denouel J, Dieterich HA, Dole WP.
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [Abstract] [Full Text] [Related]

  • 13. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R, Frishman WH, Stier CT, Sica DA.
    Cardiol Rev; 2007 Nov; 15(5):242-56. PubMed ID: 17700383
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dual inhibition of the renin system by aliskiren and valsartan.
    Birkenhäger WH, Staessen JA.
    Lancet; 2007 Jul 21; 370(9583):195-196. PubMed ID: 17658374
    [No Abstract] [Full Text] [Related]

  • 16. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS, Ziogas J, Campbell DJ.
    Hypertension; 2014 Apr 21; 63(4):768-73. PubMed ID: 24420538
    [Abstract] [Full Text] [Related]

  • 17. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP.
    Circulation; 2005 Mar 01; 111(8):1012-8. PubMed ID: 15723979
    [Abstract] [Full Text] [Related]

  • 18. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y, Matsuba S, Nako H, Nakagata N, Kaneko T, Ogawa H, Kim-Mitsuyama S.
    Hypertension; 2009 Sep 01; 54(3):633-8. PubMed ID: 19597038
    [Abstract] [Full Text] [Related]

  • 19. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
    Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    Hypertension; 2008 Sep 01; 52(3):563-72. PubMed ID: 18645051
    [Abstract] [Full Text] [Related]

  • 20. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr 01; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.